Purine derivatives for the treatment of viral infections
US-2017283419-A1 · Oct 5, 2017 · US
Compounds for treating cystic fibrosis
US10414768B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10414768-B2 |
| Application number | US-201515532309-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 4, 2015 |
| Priority date | Dec 5, 2014 |
| Publication date | Sep 17, 2019 |
| Grant date | Sep 17, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to compounds of Formula (I) or pharmaceutically acceptable enantiomers, salts, solvates or prodrugs thereof. The invention further relates to the use of the compounds of Formula (I) for the treatment of cystic fibrosis. The invention also relates to a process for manufacturing compounds of Formula (I).
First claim
Opening claim text (preview).
The invention claimed is: 1. A compound, selected from the group consisting of (S)-2-((2-chloro-9-(4-(hydroxymethyl)phenyl)-9H-purin-6-yl)amino)propanoic acid; (S)-tert-butyl 2-((2-chloro-9-(4-(hydroxymethyl)phenyl)-9H-purin-6-yl)amino)propanoate; 4-(2-chloro-6-(diethylamino)-9H-purin-9-yl)benzamide; 4-(6-amino-2-chloro-9H-purin-9-yl)benzamide; 4-(2-chloro-6-((1,3-dihydroxypropan-2-yl)amino)-9H-purin-9-yl)benzamide; (S)-2-((9-(4-carbamoylphenyl)-2-chloro-9H-purin-6-yl)amino)-3-hydroxypropanoic acid; 2-((9-(4-carbamoylphenyl)-2-chloro-9H-purin-6-yl)amino)acetic acid; tert-butyl 2-((9-(4-carbamoylphenyl)-2-chloro-9H-purin-6-yl)amino)acetate; 4-(2-chloro-6-((4-methoxybenzyl)amino)-9H-purin-9-yl)benzamide; (S)-2-((9-(4-carbamoylphenyl)-2-chloro-9H-purin-6-yl)amino)propanoic acid; (S)-tert-butyl 2-((9-(4-carbamoylphenyl)-2-chloro-9H-purin-6-yl)amino)propanoate; (4-(6-amino-2-chloro-9H-purin-9-yl)phenyl)methanol; (S)-2-((9-(4-(hydroxymethyl)phenyl)-2-((3-phenylpropyl)amino)-9H-purin-6-yl)amino)propanoic acid; and 4-(6-((4-methoxybenzyl)amino)-2-((3-phenylpropyl)amino)-9H-purin-9-yl)benzamide. 2. A pharmaceutical composition comprising a compound selected from the group consisting of (S)-2-((2-chloro-9-(4-(hydroxymethyl)phenyl)-9H-purin-6-yl)amino)propanoic acid; (S)-tert-butyl 2-((2-chloro-9-(4-(hydroxymethyl)phenyl)-9H-purin-6-yl)amino)propanoate; 4-(2-chloro-6-(diethylamino)-9H-purin-9-yl)benzamide; 4-(6-amino-2-chloro-9H-purin-9-yl)benzamide; 4-(2-chloro-6-((1,3-dihydroxypropan-2-yl)amino)-9H-purin-9-yl)benzamide; (S)-2-((9-(4-carbamoylphenyl)-2-chloro-9H-purin-6-yl)amino)-3-hydroxypropanoic acid; 2-((9-(4-carbamoylphenyl)-2-chloro-9H-purin-6-yl)amino)acetic acid; tert-butyl 2-((9-(4-carbamoylphenyl)-2-chloro-9H-purin-6-yl)amino)acetate; 4-(2-chloro-6-((4-methoxybenzyl)amino)-9H-purin-9-yl)benzamide; (S)-2-((9-(4-carbamoylphenyl)-2-chloro-9H-purin-6-yl)amino)propanoic acid; (S)-tert-butyl 2-((9-(4-carbamoylphenyl)-2-chloro-9H-purin-6-yl)amino)propanoate; (4-(6-amino-2-chloro-9H-purin-9-yl)phenyl)methanol; (S)-2-((9-(4-(hydroxymethyl)phenyl)-2-((3-phenylpropyl)amino)-9H-purin-6-yl)amino)propanoic acid; and 4-(6-((4-methoxybenzyl)amino)-2-((3-phenylpropyl)amino)-9H-purin 9 yl) and at least one pharmaceutically acceptable carrier. 3. A medicament comprising a compound selected from the group consisting of (S)-2-((2-chloro-9-(4-(hydroxymethyl)phenyl)-9H-purin-6-yl)amino)propanoic acid; (S)-tert-butyl 2-((2-chloro-9-(4-(hydroxymethyl)phenyl)-9H-purin-6-yl)amino)propanoate; 4-(2-chloro-6-(diethylamino)-9H-purin-9-yl)benzamide; 4-(6-amino-2-chloro-9H-purin-9-yl)benzamide; 4-(2-chloro-6-((1,3-dihydroxypropan-2-yl)amino)-9H-purin-9-yl)benzamide; (S)-2-((9-(4-carbamoylphenyl)-2-chloro-9H-purin-6-yl)amino)-3-hydroxypropanoic acid; 2-((9-(4-carbamoylphenyl)-2-chloro-9H-purin-6-yl)amino)acetic acid; tert-butyl 2-((9-(4-carbamoylphenyl)-2-chloro-9H-purin-6-yl)amino)acetate; 4-(2-chloro-6((4-methoxybenzyl)amino)-9H-purin-9-yl)benzamide; (S)-2-((9-(4-carbamoylphenyl)-2-chloro-9H-purin-6-yl)amino)propanoic acid; (S)-tert-butyl 2-((9-(4-carbamoylphenyl)-2-chloro-9H-purin-6-yl)amino)propanoate; (4-(6-amino-2-chloro-9H-purin-9-yl)phenyl)methanol; (S)-2-((9-(4-(hydroxymethyl)phenyl)-2-((3-phenylpropyl)amino)-9H-purin-6-yl)amino)propanoic acid; and 4-(6-((4-methoxybenzyl)amino)-2-((3-phenylpropyl)amino)-9H-purin-9-yl)benzamide. 4. A method of treatment of cystic fibrosis associated with chloride channels comprising the administration to a patient in need thereof of a compound selected from the group consisting of (S)-2-((2-chloro-9-(4-(hydroxymethyl)phenyl)-9H-purin-6-yl)amino)propanoic acid; (S)-tert-butyl 2-((2-chloro-9-(4-(hydroxymethyl)phenyl)-9H-purin-6-yl)amino)propanoate; 4-(2-chloro-6-(diethylamino)-9H-purin-9-yl)benzamide; 4-(6-amino-2-chloro-9H-purin-9-yl)benzamide; 4-(2-chloro-6-((1,3-dihydroxypropan-2-yl)amino)-9H-purin-9-yl)benzamide; (S)-2-((9-(4-carbamoylphenyl)-2-chloro-9H-purin-6-yl)amino)-3-hydroxypropanoic acid; 2-((9-(4-carbamoylphenyl)-2-chloro-9H-purin-6-yl)amino)acetic acid; tert-butyl 2-((9-(4-carbamoylphenyl)-2-chloro-9H-purin-6-yl)amino)acetate; 4-(2-chloro-6-((4-methoxybenzyl)amino)-9H-purin-9-yl)benzamide; (S)-2-((9-(4-carbamoylphenyl)-2-chloro-9H-purin-6-yl)amino)propanoic acid; (S)-tert-butyl 2-((9-(4-carbamoylphenyl)-2-chloro-9H-purin-6-yl)amino)propanoate; (4-(6-amino-2-chloro-9H-purin-9-yl)phenyl)methanol; (S)-2-((9-(4-(hydroxymethyl)phenyl)-2-((3-phenylpropyl)amino)-9H-purin-6-yl)amino)propanoic acid; and 4-(6-((4-methoxybenzyl)amino)-2-((3-phenylpropyl)amino)-9H-purin-9-yl)benzamide. 5. The method according to claim 4 , wherein the cystic fibrosis is due to a mutation of the gene encoding the CFTR protein. 6. The method according to claim 5 , wherein the cystic fibrosis is due to a deletion of the phenylalanine residue at position 508.
Assignees
Inventors
Classifications
Drugs for disorders of the respiratory system · CPC title
for pancreatic disorders, e.g. pancreatic enzymes · CPC title
Purines, e.g. adenine · CPC title
not condensed and containing further heterocyclic rings · CPC title
Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10414768B2 cover?
- The present invention relates to compounds of Formula (I) or pharmaceutically acceptable enantiomers, salts, solvates or prodrugs thereof. The invention further relates to the use of the compounds of Formula (I) for the treatment of cystic fibrosis. The invention also relates to a process for manufacturing compounds of Formula (I).
- Who is the assignee on this patent?
- Centre Nat Rech Scient, Univ Pierre Et Marie Curie—Paris 6 Upmc
- What technology area does this patent fall under?
- Primary CPC classification C07D487/04. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Sep 17 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).